Skip to main content

Advertisement

Table 1 Subject characteristics

From: Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

Characteristic non-HAD (n = 102) HAD (n = 7) P-value*
Sex (male), number (%) 101 (99) 6 (86) 0.0125
Age, years 41 (18, 68) 46 (30, 58) 0.184
CD4 cell count (×106 cells/L) 190 (0, 630) 138 (53, 344) 0.711
CPE score 8.0 (5.0, 13.0) 9.0 (6.0, 13.0) 0.060
CSF neopterin (nmol/L) 19.6 (4.0, 138.0) 54.4 (13.7, 154.0) 0.001
Blood neopterin (nmol/L) 21.7 (6.8, 77.0) 25.0 (12.0, 28.9) 0.359
CSF HIV RNA (log10 copies/mL) 3.93 (1.28, 6.26) 5.08 (3.08, 5.98) 0.015
Plasma HIV RNA (log10 copies/mL) 5.05 (1.28, 6.89) 5.31 (4.68, 5.61) 0.277
Follow-up, weeks 84.7 (0.4, 682.7) 21.6 (4.1, 150.0) 0.017
  1. Values are presented as median (range) unless stated otherwise. *Fischer exact test for categorical gender, Kruskal-Wallis test for continuous factors, and log-rank test for the length of follow-up. HAD, HIV-associated dementia; CPE: central nervous system penetration effectiveness; CSF, cerebrospinal fluid.